Study Title
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680)

Trial Description
The purpose of this research is to test the safety and efficacy of brentuximab vedotin (also known as SGN-035) in patients with acute skin graft-versus-host disease or GVHD.

This trial is sponsored by Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium/ National Cancer Institute (NCI) [1]

Study Data

  • Condition: Graft vs. Host Disease (GVHD)
  • Interventions:
  • Phase: II
  • Enrollment: 0
  • Start: September 2012
  • Estimated Primary Completion: June 2016 (Final data collection date for primary outcome measure)
  • Last verified: June 2013

Study Schematic

Screen Shot 2016-07-06 at 4.34.34 PM

Last Editorial review: July 6, 2016
Information based on (NIH/NCI) and other sources.